my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
ABSTRACT
AIMS: The objective is to develop a semi‐mechanistic disease progression model for mild cognitive impairment (MCI) subjects. The model aims to describe the longitudinal progression of ADAS‐cog scores from the Alzheimer's disease neuroimaging initiative trial that had data from 198 MCI subjects with cerebrospinal fluid (CSF) information who were followed for three years.
METHODS: Various covariates were tested on disease progression parameters and these variables fell into six categories: imaging volumetrics, biochemical, genetic, demographic, cognitive tests, and CSF biomarkers.
RESULTS: CSF biomarkers were associated with both baseline disease score and disease progression rate in subjects with MCI. Baseline disease score was also correlated with atrophy measured using hippocampal volume. Progression rate was also predicted by executive functioning as measured by the Trail B test.
CONCLUSION: CSF biomarkers have the ability to discriminate MCI subjects into sub‐populations that exhibit markedly different rates of disease progression on the ADAS‐cog scale. These biomarkers can therefore be utilized for designing clinical trials enriched with subjects that carry the underlying disease pathology.
© 2012 Janssen Pharmaceuticals, Inc. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
| Authors: | Samtani, Mahesh N.; Raghavan, Nandini; Shi, Yingqi; Novak, Gerald; Farnum, Michael; Lobanov, Victor; Schultz, Tim; Yang, Eric; DiBernardo, Allitia; Narayan, Vaibhav A.; | |
| Journal: | British Journal of Clinical Pharmacology | |
| Year: | 2012 | |
| Pages: | no | |
| DOI: | 10.1111/j.1365-2125.2012.04308.x | |
| Publication date: | 26-04-2012 |
Watchlist
This is where you can add this publication to your personal favourites.
Additional Information
Cancer risks for MLH1 and MSH2 mutation carriers
ABSTRACT We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation‐carrying families from the Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial cancer (EC) and other cancers for carriers were estimated using modified segregation analysis co ... more
Scope Flavonoids have well‐known antioxidant, anti‐inflammatory, and anti‐cancer activities. Isoflavone genistein is considered a potent antioxidant agent against oxidative stress. Although several mechanisms have been proposed, a clear antioxidant mechanism of genistein is still remain ... more
Abstract People can get oral cancers from UV (290‐400 nm) exposures. Besides high outdoor UV exposures, high indoor UV exposures to oral tissues can occur when consumers use UV‐emitting tanning devices to either tan or whiten their teeth. We compared the carcinogenic risks of skin to or ... more
Marijuana use may increase risk of testicular cancer
A new study from the University of Southern California (USC) has found a link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer that tend to carry a somewhat worse prognosis. Published in CANCER the findings suggest that the potential cance ... more
New Study into Bladder Regeneration Heralds Organ Replacement Treatment
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient’s own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also ... more
Stem Cells journal awards human cord-blood research
The journal Stem Cells has announced Dr. Cinzia Rota as the winner of the annual Stem Cells Young Investigator Award. Co-sponsored by the International Stem Cell Symposium, the $10,000 prize is annually given to a young scientist who is the principal author of a research paper published in ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
